15 results
8-K
IMGN
Immunogen, Inc.
5 May 23
Entry into a Material Definitive Agreement
5:15pm
in the ELAHERE arm, compared to 12.75 months in the IC chemotherapy arm, with a hazard ratio (“HR”) of 0.67, p=0.0046. This represents a 33% reduction … meaningful improvement in PFS by investigator assessment compared to IC chemotherapy, with a hazard ratio of 0.65 (p<0.0001), which represents a 35
424B5
IMGN
Immunogen, Inc.
5 May 23
Prospectus supplement for primary offering
4:49pm
months in the ELAHERE arm, compared to 12.75 months in the IC chemotherapy arm, with a hazard ratio (HR) of 0.67, p=0.0046. This represents a 33 … and clinically meaningful improvement in PFS by investigator assessment compared to IC chemotherapy, with a hazard ratio of 0.65 (p<0.0001), which represents
424B5
IMGN
Immunogen, Inc.
3 May 23
Prospectus supplement for primary offering
4:05pm
, 2023, the median OS was 16.46 months in the ELAHERE arm, compared to 12.75 months in the IC chemotherapy arm, with a hazard ratio (HR) of 0.67, p=0.0046 … a statistically significant and clinically meaningful improvement in PFS by investigator assessment compared to IC chemotherapy, with a hazard ratio of 0.65 (p<
8-K
EX-99.1
bdlivb
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
EX-99.1
ft6 7y0qwo
13 Jan 20
Results of Operations and Financial Condition
6:07am
8-K
EX-99.3
qggzg3hool5rwio9bt
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
424B5
zqeemt
12 Jul 12
Prospectus supplement for primary offering
12:00am
424B5
2pkec
12 Jul 12
Prospectus supplement for primary offering
12:00am
10-K405
EX-10.7
09a54 bg9ubwmqxa8r
26 Sep 97
Annual report (delinquent filer disclosure)
12:00am
- Prev
- 1
- Next